Related Experiment Video
Updated: Aug 19, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells
Abstract:
Glioma is a deadly form of brain cancer, and the difficulty of treating glioma is exacerbated by the chemotherapeutic resistance developed in the tumor cells over the time of treatment. siRNA can be used to silence the gene responsible for the increased resistance, and sensitize the glioma cells to drugs. Here, iron oxide nanoparticles functionalized with peptides (NP-CTX-R10) were used to deliver siRNA to silence O6-methylguanine-DNA methyltransferase (MGMT) to sensitize tumor cells to alkylating drug, Temozolomide (TMZ). The NP-CTX-R10 could complex with siRNA through electrostatic interactions and was able to deliver the siRNA to different glioma cells. The targeting ligand chlorotoxin and cell penetrating peptide polyarginine (R10) enhanced the transfection capability of siRNA to a level comparable to commercially available Lipofectamine. The NP-siRNA was able to achieve up to 90% gene silencing. Glioma cells transfected with NP-siRNA targeting MGMT showed significantly elevated sensitivity to TMZ treatment. This nanoparticle formulation demonstrates the ability to protect siRNA from degradation and to efficiently deliver the siRNA to induce therapeutic gene knockdown.
Insights
Iron oxide nanoparticles deliver siRNA to silence the MGMT gene in glioma cells, overcoming drug resistance. This approach significantly enhances the effectiveness of Temozolomide chemotherapy for brain cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Glioma is a fatal brain cancer with limited treatment options.
- Chemotherapeutic resistance, particularly to alkylating agents like Temozolomide (TMZ), is a major challenge in glioma treatment.
- Silencing the O6-methylguanine-DNA methyltransferase (MGMT) gene can resensitize glioma cells to TMZ.
Purpose of the Study:
- To develop and evaluate iron oxide nanoparticles (NP-CTX-R10) for delivering siRNA to silence the MGMT gene in glioma cells.
- To enhance the delivery and transfection efficiency of siRNA using peptide-functionalized nanoparticles.
- To assess the combined therapeutic effect of MGMT gene silencing and TMZ treatment on glioma cells.
Main Methods:
- Iron oxide nanoparticles were functionalized with chlorotoxin and polyarginine (NP-CTX-R10) to complex with siRNA via electrostatic interactions.
- The NP-siRNA formulation was tested for its ability to transfect various glioma cells.
- Gene silencing efficiency of siRNA targeting MGMT was quantified, and the sensitivity of transfected cells to TMZ was evaluated.
Main Results:
- NP-CTX-R10 nanoparticles efficiently delivered siRNA to glioma cells, achieving up to 90% MGMT gene silencing.
- The peptide-functionalized nanoparticles demonstrated transfection capabilities comparable to commercial Lipofectamine.
- Glioma cells treated with NP-siRNA targeting MGMT showed significantly increased sensitivity to TMZ, indicating enhanced therapeutic efficacy.
Conclusions:
- Peptide-functionalized iron oxide nanoparticles are effective carriers for siRNA delivery in glioma treatment.
- This nanoparticle formulation protects siRNA from degradation and facilitates efficient gene knockdown.
- The combined approach of siRNA-mediated MGMT silencing and TMZ chemotherapy holds promise for overcoming drug resistance in glioma.
